Abstract
Over the last decade, numerous basic biological as well as experimental and clinical studies have firmly established the significance of tumor necrosis factor (TNF) as a principal proximal mediator of sepsis. Originally identified as a tumoricidal agent, TNF is now recognized as a major inflammatory cytokine with pleiotropic activities on many cell types and organs, which is involved in the local physiological host immune response to invading micro-organisms as well as in the pathophysiology of systemic inflammatory conditions, such as sepsis [1–4]. Highly elevated systemic levels of TNF, as observed during sepsis and septic shock, induce a wide range of immunological and metabolic sequelae, that result in tissue injury, eventually culminating in multiple organ dysfunction with high mortality. The accumulated evidence for the central involvement of TNF in the pathogenesis of septic shock has led many researchers, molecular biologists and clinicians alike, to investigate the complex mechanisms that regulate the production and release of TNF, and that determine its biological effects. The goals of such research efforts are to gain more insight into the pathophysiology of critical illnesses, to develop sensitive and rapid diagnostic tests, and ultimately to provide new therapeutic strategies from which the critically-ill may benefit.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bemelmans MHA, Van Tits LJH, Buurman WA (1996) Tumor necrosis factor: function, release and clearance. Crit Rev Immunol 16: 1–11
Strieter RM, Kunkel SL, Bone RC (1993) Role of tumor necrosis factor-a in disease states and inflammation. Crit Care Med 21: S447—S463
Tracey KJ, Cerami A (1993) Tumor necrosis factor: An updated review of its biology. Crit Care Med 21: S415—S422
Beutler B, Grau GE (1993) Tumor necrosis factor in the pathogenesis of infectious dis-eases. Crit Care Med 21: S423—S435
Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Eng J Med 334: 1717–1725
Dembic Z, Loetscher H, Gubler U, Pan YCE, Lahm HW, Gentz R, Brockhaus M, Less-lauer W (1990) Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 2: 231–237
Tartaglia LA, Goeddel DV (1992) Two TNF receptors. Immunol Today 13: 151–153
Leeuwenberg JFM, Van Tits LJH, Jeunhomme TMMA, Buurman WA (1995) Evidence for exclusive role in signalling of tumour necrosis factor p55 receptor and a potentiating function of p75 receptor on human endothelial cells. Cytokine 7: 457–462
Barbara JAJ, Smith WB, Gamble JR, Van Ostade X, Vandenabeele P, Tavernier J, Fiers W, Vadas MA, Lopez AF (1994) Dissociation of TNF-a cytotoxic and proinflammatory activities by p55 receptor-and p75 receptor-selective TNF-a mutants. EMBO J 13: 843–850
Van Tits LJ, Bemelmans MH, Steinshamn S, Waage A, Leeuwenberg JF, Buurman WA (1994) Non-signaling functions of TNF-R75: findings in man and mouse. Circ Shock 44: 40–44
Van der Poll T, Jansen J, Van Leenen D, Von der Möhlen M, Levi M, Ten Cate H, Gallati H, Ten Cate JW, Van Deventer SJ (1993) Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 168: 955–960
Aderka D, Engelmann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G (1991) Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 51: 5602–5607
Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM (1994) Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 24: 2699–2705
Porteu F, Hieblot C (1994) Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J Biol Chem 269: 2834–2840
Higuchi M, Aggarwal BB (1994) TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol 152: 3550–3558
Lantz M, Malik S, Slevin ML, Olsson I (1990) Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 2: 402–406
Lantz M, Gullberg U, Nilsson E, Olsson L (1990) Characterization in vitro of a human tumor necrosis factor-binding protein. J Clin Invest 86: 1396–1442
Spinas GA, Keller U, Brockhaus M (1992) Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 90: 533–536
Girardin E, Roux-Lombard P, Grau GE, Suter P, Galati H, Dayer JM (1992) Imbalance between tumour necrosis factor-a and soluble TNF receptor concentrations in severe meningococcocaemia. Immunology 76: 20–23
Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer L, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-alpha in vitro and in vivo. Proc Natl Acad Sci USA 89: 4845–4849
Vossen ACTM, Tibbe GJM, Buurman WA, Benner R, Savelkoul HFJ (1996) Soluble tumor necrosis factor receptor release after anti-CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor-a release. Eur Cytokine Netw 7: 751–755
Bemelmans MHA, Abramowicz D, Gouma DJ, Goldman M, Buurman WA (1994) In vivoT cell activation by anti-CD3 mAb induces soluble TNF receptor release in mice: effects of pentoxifylline, methylprednisolone, anti-TNF and anti-INF-y antibodies. J Immunol 153: 499–506
Leeuwenberg JFM, Jeunhomme TMMA, Buurman WA (1994) Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 152: 4036–4043
Lien E, Liabakk NB, Johnsen AC, Nonstad U, Sundan A, Espevik T (1995) Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. Eur J Immunol 25: 2714–2717
Leeuwenberg JFM, Dentener MA, Buurman WA (1994) Lipopolysaccharide-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS Binding Protein, and Bactericidal/Permeability-increasing Protein. J Immunol 152: 5070–5076
Redl H, Schlag G, Paul E, Bahrami S, Buurman WA, Strieter RM, Kunkel SL, Davies J, Foulkes R (1996) Endogenous modulators of TNF and IL-1 response are under partial control of TNF in baboon bacteremia. Am J Physiol 271: R1193—R1198
Bemelmans MHA, Gouma DJ, Buurman WA (1993) LPS-induced sTNF-receptor release in vivo in a murine model: investigation of the role of TNF, IL-1, LIF, and IFN-y. J Immunol 151: 5554–5562
Steinshamn S, Bemelmans MHA, Buurman WA, Waage A (1995) Granulocytopenia reduces release of soluble TNF receptor p75 in endotoxin-stimulated mice: a possible mechanism of enhanced TNF activity. Cytokine 7: 50–56
Redl H, Schlag G, Schiesser A, Davies J (1995) Thrombomodulin release in baboon sepsis: its dependence on the dose of Escherichia coli and the presence of tumor necrosis factor. J Infect Dis 171: 1522–1527
Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A (1986) Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232: 977–980.
Carpenter A, Evans TJ, Buurman WA, Bemelmans MH, Moyes D, Cohen J (1995) Differences in the shedding of soluble TNF receptors between endotoxin-sensitive and endotoxin-resistant mice in response to lipopolysaccharide or live bacterial challenge. J Immunol 155: 2005–2012
Van der Poll T, Fischer E, Coyle SM, Van Zee KJ, Pribble JP, Stiles DM, Barie PS, Buur-man WA, Moldawer LL, Lowry SF (1995) Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis. J Infect Dis 172: 577–580
Porteu F, Nathan C (1990) Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172: 599–607
Ding AH, Porteu F (1992) Regulation of tumor necrosis factor receptors on phagocytes. P Soc Exp Biol Med 200: 458–465
Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan C (1991) Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. J Biol Chem 266: 18846–18853
Landmann R, Keilholz U, Scheibenbogen C, Brockhaus M, Gallati H, Denz H, Bargetzi M, Ludwig C. (1994) Relationship between soluble tumor necrosis factor (TNF) receptors and TNF alpha during immunotherapy with interleukin-2 and/or interferon alpha. Cancer Immunol Immunother 38: 113–118
Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW (1994) Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83: 113–118
Lantz M, Björnberg F, Olsson I, Richter J (1994) Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J Immunol 152: 1362–1369
Scannell G, Waxman K, Kaml GJ, loli G, Gatanaga T, Yamamoto R, Granger GA (1993) Hypoxia induces a human macrophage cell line to release tumor necrosis factor-a and its soluble receptors in vitro. J Surg Res 54: 281–285
Tan LR, Waxman K, Scanell G, Loli G, Granger GA (1993) Trauma causes early release of soluble receptors for tumor necrosis factor. J Trauma 34: 634–638
Cinat ME, Waxman K, Granger GA, Pearce W, Annas C, Daughters K (1994) Trauma causes sustained elevation of soluble tumor necrosis factor receptors. J Am Coll Surg 179: 529–537
Rogy MA, Coyle SM, Oldenburg HS, Rock CS, Barie PS, Van Zee KJ, Smith CG, Moldawer LL, Lowry SF (1994) Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 178: 132–138
Lowry SF, Van Zee KJ, Rock CS, Thompson WA, Oldenburg HSA, Rogy MA, Moldawer LL (1993) Tumor necrosis factor as a mediator of sepsis. In: G Schlag, H Redl, DL Traber (eds): Shock, sepsis and organ failure. Springer-Verlag, Berlin, Heidelberg, 3–17
Peetre C, Thysell H, Grubb A, Olsson I (1988) A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol 41: 414–419
Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175: 323–329
Ding AH, Sanchez E, Srimal S, Nathan CF (1989) Macrophages rapidly internalize their tumor necrosis factor receptors in response to lipopolysaccharide. J Biol Chem 264: 3924–3929
Bemelmans MHA, Gouma DJ, Buurman WA (1993) Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 150: 2007–2017
Bemelmans MHA, Gouma DJ, Buurman WA (1994) Tissue distribution and clearance of soluble murine TNF receptors in mice. Cytokine 6: 608–615
Brockhaus M, Bar-Khayim Y, Gurwicz S, Frensdorff A, Haran N (1992) Plasma tumor necrosis factor soluble receptors in chronic renal failure. Kidney Int 42: 663–667.
Froon AHM, Bemelmans MHA, Greve JW, Van der Linden CJ, Buurman WA (1994) Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med 22: 803–809
Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151: 1548–1561
Olsson I, Gatanaga T, Gullberg U (1993) Tumor necrosis factor binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Network 4: 169–180
Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D (1995) Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 54: 1–8
Brockhaus M (1997) Soluble TNF receptor: what is the significance? Intensive Care Med 23: 808–809
De Beaux AC, Goldie AS, Ross JA, Carter DC, Fearon KC (1996) Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 83: 349–353
Kaufmann P, Tilz GP, Lueger A, Demel U (1997) Elevated plasma levels of soluble tumor necrosis factor receptor (sTNFRp60) reflect severity of acute pancreatitis. Intensive Care Med 23: 841–848
Van Deuren M, Van der Ven-Jongekrijg J, Demacker PMN, Bartelink AK, Van Dalen R, Sauerwein RW, Gallati H, Vannice JL, Van der Meer JW (1994) Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 169: 157–161
Bemelmans MHA, Greve JW, Gouma DJ, Buurman WA (1996) Increased concentrations of tumour necrosis factor (TNF) and soluble TNF receptors in biliary obstruction in mice; soluble TNF receptors as prognostic factors for mortality. Gut 38: 447–453
Pilz G, Fraunberger P, Appel R, Kreuzer E, Werdan K, Walli A, Seidel D (1996) Early prediction of outcome in score-identified, postcardiac surgical patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations. Crit Care Med 24: 596–600
Engelberts I, Möller A, Schoen GJM, Van der Linden CJ, Buurman WA (1991) Evaluation of measurement of human TNF in plasma by ELISA. Lymphokine Cytokine Res 10: 69–76
Engelberts I, Stephens S, Francot GJM, Van der Linden CJ, Buurman WA (1991) Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 338: 515–516
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Basel AG
About this chapter
Cite this chapter
Bouma, M.G., Buurman, W.A. (1999). Soluble TNF receptors. In: Redl, H., Schlag, G. (eds) Cytokines in Severe Sepsis and Septic Shock. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8755-7_7
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8755-7_7
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9759-4
Online ISBN: 978-3-0348-8755-7
eBook Packages: Springer Book Archive